

# Technical Data Sheet

## InVivoMAb anti-SARS-CoV-2 S protein (RBD)



**Attention:** Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at <https://bioxcell.com/terms-and-conditions>.

### Lot Specific Information

**Lot Number:** Lot Specific\*  
**Volume:** Lot Specific\*  
**Concentration:** Lot Specific\* (generally 4 to 11 mg/ml) \*  
**Total Protein:** Lot Specific\*

\*This information will be noted on the certificate of analysis that ships with this product.

### Product Information

**Catalog Number:** BE0438  
**Clone:** SARS2-38  
**Isotype:** Mouse IgG1,  $\kappa$   
**Recommended Isotype Control(s):** InVivoMAb mouse IgG1 isotype control, unknown specificity  
**Recommended Dilution Buffer:** InVivoPure pH 7.0 Dilution Buffer  
**Immunogen:** SARS-CoV-2 RBD and SARS-CoV-2 spike protein  
**Reported Applications:** *in vivo* neutralization of SARS-CoV-2 variants  
*in vitro* neutralization of SARS-CoV-2 variants  
Focus reduction neutralization test (FRNT)  
Flow cytometry  
ELISA  
Inhibition of viral attachment on cells  
Focus forming assay (FFA)  
**Formulation:** PBS, pH 7.0  
Contains no stabilizers or preservatives  
**Endotoxin:** <2EU/mg (<0.002EU/ $\mu$ g)  
Determined by LAL gel clotting assay  
**Purity:** >95%  
Determined by SDS-PAGE  
**Sterility:** 0.2  $\mu$ m filtration  
**Production:** Purified from cell culture supernatant in an animal-free facility  
**Purification:** Protein G  
**RRID:**  
**Molecular Weight:** 150 kDa

### Description

The SARS2-38 monoclonal antibody reacts with many variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19). SARS-CoV-2 vaccines and neutralizing monoclonal antibodies have been great tools for controlling the COVID-19 pandemic however, the emerging SARS-CoV-2 variants often exhibit mutations in the spike protein, conferring resistance to antibodies elicited by vaccines or natural infections. The SARS2-38 monoclonal antibody binds a conserved epitope on the RBD (amino acids K444 and G446). Targeting this conserved region with SARS-CoV-2 vaccines or neutralizing antibodies is suggested to confer protection against infections with SARS-CoV-2 variants. The SARS2-38 monoclonal antibody is a potently neutralizing antibody that does not cross-react with the SARS-CoV-1 spike protein. The SARS2-38 monoclonal antibody is reported to inhibit the attachment of SARS-CoV-2 to Vero E6, Vero-TMPRSS2, Vero-TMPRSS2-ACE2, or Calu-3 cells and the virus internalization in Vero E6 cells *in vitro*. In animal studies, a single 100- $\mu$ g *in vivo* injection of SARS2-38 monoclonal antibody to K18 human ACE2 (hACE2) transgenic mice 24 hours before the intranasal inoculation of SARS-CoV-2 WA1/2020 decreased the levels of viral RNA,

cytokines, and chemokines.

## Storage

Store at the stock concentration at 4°C. **Do not freeze.**

It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at <https://bioxcell.com/faqs>.

## Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

## Application References

For a complete list of references, visit [https://bioxcell.com/be0438?bxcs=9k1b3a#tab\\_references](https://bioxcell.com/be0438?bxcs=9k1b3a#tab_references) or scan the QR code below.



---

**Bio X Cell, LLC**

<https://bioxcell.com>

+1-866-787-3444

[customerservice@bioxcell.com](mailto:customerservice@bioxcell.com)

*Conditions: For research use only. Not for use in diagnostic or therapeutic procedures.*

*Not for resale.*

**Bio X Cell, Bio X Cell logo, and all other trademarks are the property of Bio X Cell, LLC © 2024 Bio X Cell, LLC**